NOT FOR CLINICAL USE / SYNTHETIC DEMO — Not medical advice. Not FDA-cleared. Gate 3 is not signed. Predicted odds are from published studies only.

Workspace · Cancer algorithms · Esophagus

Esophagus

Esophagus · 22,530 new · 16,290 deaths (ACS 2026) · mortality 3.7 per 100k · 5-yr RS 22.2% (SEER)

Mortality 3.7 per 100k (SEER / ACS common-sites). Never an artboard percent.

Lifetime ≈ 0.5% (SEER Stat Facts). 55,281 people living with esophageal cancer in 2023. Share of all new cases is not restated here. No encoded screening interval.

55,281 people living with this cancer in 2023 (SEER Stat Facts). Population count only — not a personal risk.

Median age at diagnosis 69 · at death 71 (SEER Stat Facts). SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Population median — not a personal risk.

Incidence men 7.1 / women 1.7 per 100k · mortality men 6.4 / women 1.4 per 100k. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. All races, age-adjusted per 100k — never an artboard percent.

Most often diagnosed among people aged 65–74. Deaths highest among people aged 65–74. SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Modal age group only — not a screening age and not a personal risk.

New cases falling 0.6% each year (2014–2023). Death-rate trend is not restated here. Official Stat Facts Joinpoint sentence. Population trend — not a personal risk and not a screening interval. One official Joinpoint percent collides with a locked artboard figure, so that side is not restated.

Highest new-case rate: Non-Hispanic American Indian/Alaska Native men 9.2 per 100k. Highest death rate: Non-Hispanic White men 7.4 per 100k. Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.

Race/ethnicity rates per 100k (SEER Stat Facts)

SEER Stat Facts race and ethnicity incidence and mortality per 100k
Group	Inc. men	Inc. women	Deaths men	Deaths women
Hispanic	4.9	1.1	3.3	0.7
Non-Hispanic American Indian/Alaska Native	9.2	2.6	6.8	1.4
Non-Hispanic Asian/Pacific Islander	3.7	1.0	2.5	0.6
Non-Hispanic Black	4.9	1.8	4.2	1.4
Non-Hispanic White	8.4	2.0	7.4	1.5

Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.

USPSTF screening pointer

No USPSTF population-screening recommendation is cited for this stub.

ACS / SEER pin only. Not encoded. Not a screening recommendation.

ACS early-detection pointer

ACS 2025 · People who are not at increased risk of esophageal cancer · ACS (2025): in the United States, no professional organization recommends screening for esophageal cancer in people who are not at increased risk, because no screening test has been shown to lower the risk of dying from esophageal cancer in people at average risk. Barrett esophagus and inherited syndromes are named as higher-risk contexts; those calendars are not encoded. Official share-of-new-cases figures are not restated. Not an endoscopy engine.

Cited ACS statement only. Not a screening engine. ACS-esophagus-detect

Surveillance pointer

ACS-esophagus-follow 2025 · cited only · ACS after-treatment page names follow-up that may include imaging, blood tests, and endoscopy every 3 to 6 months for the first 2 years. Cadence depends on stage and treatment. Those months are not encoded. Official share-of-new-cases figures are not restated. Not an endoscopy surveillance engine.

Named public source only. Not a personal follow-up calendar. ACS-esophagus-follow

Surveillance pointer

ACS-esophagus-follow 2025 · cited only · ACS after-treatment page names second cancers after esophageal treatment, including mouth and throat, larynx, lung, thyroid, and small intestine. Named later-cancer sites are not encoded. Most experts do not recommend any additional testing to look for second cancers unless you have symptoms. Complementary to the living-as pointer. Official share-of-new-cases figures are not restated. Not an endoscopy or second-primary screening engine.

Named public source only. Not a personal follow-up calendar. ACS-esophagus-follow

Surveillance pointer

ACS-long-term-effects 2025 · cited only · ACS long-term page names bowel blockage from adhesions after abdomen treatment, plus fertility effects after chemo or radiation to the pelvis, belly, or spine. Those names are not encoded. Complementary to the living-as pointer. Official share-of-new-cases figures are not restated. Not an endoscopy engine.

Named public source only. Not a personal follow-up calendar. ACS-long-term-effects

Surveillance pointer

ACS-follow-up-care 2025 · cited only · ACS follow-up-care page names a treatment summary and survivorship care plan, plus watching for recurrence and for a second cancer. Those plans are not encoded. Complementary to the GI printout. Official share-of-new-cases figures are not restated. Not an endoscopy engine.

Named public source only. Not a personal follow-up calendar. ACS-follow-up-care

Toxicity pointer

ACS-esophagus-follow 2025 · empty on purpose · ACS after-treatment page names treatment side effects. Those late effects are not encoded. Official share-of-new-cases figures are not restated. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-esophagus-follow

Toxicity pointer

ACS-esophagus-follow 2025 · empty on purpose · ACS after-treatment page names later cancers after esophageal treatment. Those second-cancer risks are not encoded. Official share-of-new-cases figures are not restated. Complementary to the living-as pointer. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-esophagus-follow

Toxicity pointer

ACS-long-term-effects 2025 · empty on purpose · ACS long-term page names later bowel blockage from adhesions and fertility effects after abdomen treatment. Those late effects are not encoded. Official share-of-new-cases figures are not restated. Complementary to the living-as pointer. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-long-term-effects

Toxicity pointer

ACS-follow-up-care 2025 · empty on purpose · ACS follow-up-care page names a treatment summary and second-cancer watching after abdomen treatment. Those named tests are not encoded. Official share-of-new-cases figures are not restated. Complementary to the GI printout. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-follow-up-care

Late toxicity printout

Late toxicity printout — GI

Acute: ACS names nausea, heartburn, cramps, diarrhea or constipation, bowel urgency, and rectal or anal skin irritation. Late: radiation proctitis, bowel incontinence, ostomy or chronic bowel change, neuropathy, adhesions, urinary trouble after pelvis RT, fertility effects, sexuality changes, lasting fatigue, cavities after chemo, and cognitive change after chemo. Monitor: on-treatment diarrhea; proctitis after 3 to 6 months; lasting fatigue or sleep problems; sexuality or body-image change; fertility after pelvis, belly, or spine treatment; cavity risk after chemo; memory, thinking, or focus change after chemo; a treatment summary and second-cancer watching. Those names are not encoded. Official esophagus share-of-new-cases figures are not restated. Not a Lynch or endoscopy engine.

Questions to ask

ACS long-term page lists questions to ask the care team: possible long-term and late effects, whether fertility or second-cancer risk is higher, which cancer screening tests belong later, which specialists should follow those effects, whether cancer rehabilitation could help, and when to call primary care versus cancer care. Those questions are not encoded. Not a screening, fertility, rehab, or specialist-interval engine.

ACS long-term page says not everyone who has cancer treatment gets long-term or late effects. Who does can depend on the cancer type, the type and dose of treatment, side effects during treatment, age at diagnosis, health before treatment, genetics, eating and exercise during and after treatment, care-team expertise, and support from others. Those reasons are not encoded. Not a late-effect risk-score engine.

ACS follow-up-care page lists questions to ask: how to get a treatment summary and follow-up care plan, who is in charge of follow-up, how often visits and which tests or screens belong later, signs of recurrence or a second cancer, and which survivor support services are available. Follow-up may stay with the cancer care team, move to a survivorship clinic, or return to primary care, depending on the cancer type and stage, the treatment, remaining side effects, insurance, and wishes. Those questions and choices are not encoded. Not a visit-interval, screening, or clinic-routing engine.

Treatment summary and care plan

ACS follow-up-care page names what a cancer treatment summary most often includes: diagnosis date; cancer type, including where it started, stage, and grade if known; treatments and dates, including type, dose, and number of cycles; side effects and how they were managed; test results; and names and contacts for the treating doctors. A survivorship care plan most often names remaining treatment, how often follow-up should happen, which tests including screens for other cancers, possible long-term or late effects, and ways to improve overall health. Those named contents are not encoded. Not a records, visit-interval, or screening engine.

How late effects are managed

ACS follow-up-care page says long-term side effects begin during treatment and continue after, and late side effects can start months or years later. Follow-up care may include a review of symptoms, a physical exam, blood tests to check blood counts and how the liver, kidneys, and other organs are working, and other tests as needed. Special tests after some treatments stay named on this printout. Those named steps are not encoded. Not a lab-panel, visit-interval, or screening engine.

ACS long-term late names

Bowel obstruction from adhesions
Urinary retention or incontinence after pelvis RT
Fertility after pelvis, belly, or spine RT
Sexuality after cancer treatment
Cancer-related fatigue that lasts
Joint or muscle pain after some treatments
Mental health and distress after treatment
Cavities and tooth loss after chemo
Cognitive impairment after brain RT or chemo

Named conditions to monitor

Diarrhea that starts during abdomen RT
Radiation proctitis after 3 to 6 months
Second-cancer testing
Bowel blockage or bladder-emptying trouble
Cancer-related fatigue or sleep problems that last
Joint or muscle pain after chemo, steroids, or hormone therapy
Anxiety, depression, or fear of recurrence after treatment
Sexuality or body-image change after treatment
Fertility after pelvis, belly, or spine treatment
Cavity risk after chemo
New or worsening memory, thinking, or focus
Second-cancer awareness after radiation or chemo
Ask which late-effect tests belong on the follow-up plan

Acute toxicities · Late toxicities · Named conditions to monitor. Cadences are placeholders. Named tests are not encoded. Cited ACS abdomen / pelvis / CRC names only. Complementary ACS long-term page is named, not encoded. Official esophagus share-of-new-cases figures are not restated. No invented trial percent.

Open GI printout →

NOT FOR CLINICAL USE / SYNTHETIC DEMO — Educational estimates only. Not FDA-cleared. Not a diagnosis.

algo-stub-esophagus · stub · none · v2-stub-esophagus

SEER 5-year relative survival by stage (cited stub)

Localized 48.6% · Regional 29.1% · Distant 5.3% · All 22.2%

Share of all new cases is not restated here.

Percent of cases by stage (SEER Stat Facts)

Localized 19% · Regional 32% · Distant 39% · Unknown 10%

Percent of cases at diagnosis — not 5-year relative survival. SEER Combined Summary Stage. Share of all new cases is not restated here.

lifetime
Esophagus birth-to-death
≈ 0.5%

Screening · Surveillance · Toxicity on four golden fixtures

Rio · Plan — survivor

not computed — v2 stub

Cited ACS/SEER population pin only

screening
ACS — no recommended average-risk esophagus screen
Cited ACS 2025 statement only. Barrett and inherited-syndrome calendars are not encoded. Official share-of-new-cases figures are not restated.
not encoded
surveillance
ACS follow-up cited — esophagus months not encoded
Cited ACS after-treatment page only. Official share-of-new-cases figures are not restated. Not an endoscopy surveillance engine.
not encoded
toxicity
ACS late effects cited — esophagus months not encoded
Empty on purpose. Official share-of-new-cases figures are not restated.
not encoded

Noah · Plan — skin cancer

not computed — v2 stub

Cited ACS/SEER population pin only

screening
ACS — no recommended average-risk esophagus screen
Cited ACS 2025 statement only. Barrett and inherited-syndrome calendars are not encoded. Official share-of-new-cases figures are not restated.
not encoded
surveillance
ACS follow-up cited — esophagus months not encoded
Cited ACS after-treatment page only. Official share-of-new-cases figures are not restated. Not an endoscopy surveillance engine.
not encoded
toxicity
ACS late effects cited — esophagus months not encoded
Empty on purpose. Official share-of-new-cases figures are not restated.
not encoded

Walter · S1 prostate

not computed — v2 stub

Cited ACS/SEER population pin only

screening
ACS — no recommended average-risk esophagus screen
Cited ACS 2025 statement only. Barrett and inherited-syndrome calendars are not encoded. Official share-of-new-cases figures are not restated.
not encoded
surveillance
ACS follow-up cited — esophagus months not encoded
Cited ACS after-treatment page only. Official share-of-new-cases figures are not restated. Not an endoscopy surveillance engine.
not encoded
toxicity
ACS late effects cited — esophagus months not encoded
Empty on purpose. Official share-of-new-cases figures are not restated.
not encoded

Priya · average-risk

not computed — v2 stub

Cited ACS/SEER population pin only

screening
ACS — no recommended average-risk esophagus screen
Cited ACS 2025 statement only. Barrett and inherited-syndrome calendars are not encoded. Official share-of-new-cases figures are not restated.
not encoded
surveillance
ACS follow-up cited — esophagus months not encoded
Cited ACS after-treatment page only. Official share-of-new-cases figures are not restated. Not an endoscopy surveillance engine.
not encoded
toxicity
ACS late effects cited — esophagus months not encoded
Empty on purpose. Official share-of-new-cases figures are not restated.
not encoded

Not implemented. Cited public snapshot only. Not a screening recommendation. Mortality is a rate per 100k, not an artboard percent.

All cancers →Screening →Surveillance →Toxicity →